Innovative Method for Bulk Production of Sphingolipids
ApplicationOptically pure D-erythro-Sphingosine that can be produced with high yield. Key Benefits - Method efficiently produces D-erythro-Sphingosine and derivatives in bulk and with high optical purity.
- D-erythro-Sphingosine can be converted to many other sphingolipids for use in the production of therapeutics and cosmetics.
Technical Summary Sphingolipids are cell membrane components involved in cell processes ranging from cell growth and apoptosis to stress response, calcium homeostasis, and angiogenesis. Many naturally occurring sphingolipids exhibit therapeutic properties such as antibacterial, antifungal or antitumoral properties presenting novel avenues for drug development. A major drawback to their use as therapeutic compounds however is an inability to produce the sphingolipids in useful quantities efficiently, either by isolation from nature or synthesis in the laboratory. This invention addresses these concerns, providing a new high-yield synthesis method for producing optically pure D-erythro-Sphingosine, the backbone component of sphingolipids. The new method employed begins with an N-protected Serine, which is then converted through a series of mild reactions to D-erythro-Sphingosine. By adding racemic inhibitors and catalytic compounds during key steps, this method of synthesis produces a 99% optically pure product with a-high yield. The D-erythro-Sphingosine can then be converted to a host of sphingolipids including phosphate sphingosines, ceramides, and glycolipids, each with their own possible therapeutic uses. Developmental Stage This technology has been used to produce large quantities of optically pure D-erythro-Sphingosine in the laboratory.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
| Nationalized PCT - United States |
United States |
12/440,285 |
7,960,589 |
3/6/2009 |
6/14/2011 |
Issued |
|
|
